Verita Healthcare Group has been named Integrative Healthcare Group of the Year in Asia-Pacific 2026 and Health Tech Innovator of the Year in Asia-Pacific 2026 at the Global Health Asia-Pacific Awards.

The dual recognition reflects work across the Group’s specialist brands – Verita Life, Verita Neuro, Verita Health and Regenetec – and the clinicians, scientists, partners and patients behind it.

Highlights include the publication of Verita Neuro‘s Phase II Epidural Electrical Stimulation trial in the Journal of Central Nervous System Disease in collaboration with the University of São Paulo, the regional launch of the FDA-cleared ReWalk® 7 Personal Exoskeleton through an exclusive partnership with NASDAQ-listed Lifeward, and the introduction of VIBA™ – the Verita Index of Biological Age – developed in collaboration with the University of Vienna.

Verita will be featured in an upcoming edition of Global Health Asia-Pacific magazine.

Find out more at: https://www.globalhealthandtravel.com/